The overall goal of the City of Hope Lymphoma Specialized Program of Research Excellence (SPORE) is to develop novel therapies and preventative strategies to combat lymphoma, and rapidly advance them from laboratory studies to human clinical trials. This “bench-to-bedside” approach is known as translational science and the SPORE Program is part of the National Cancer Institute’s Translation Research Program (TRP). The TRP currently funds 64 SPOREs across the US, covering 18 organ sites; City of Hope holds one of only 4 lymphoma-focused SPOREs.
Our SPORE consists of 4 translational research projects, 4 core resources and 2 award programs to foster new projects and investigators. An important theme of the translational studies in this grant is developing lymphoma therapies that are more patient-tailored and less toxic than conventional treatment regimens for Hodgkin and non-Hodgkin lymphoma.
The City of Hope Lymphoma SPORE is comprised of the following Projects and Cores:
Project: Therapy-Related Leukemia Following Autologous Transplantation for Lymphoma
Project Leaders: Ravi Bhatia, M.D.; Timothy O’Connor, Ph.D.; Smita Bhatia, M.D.
Project: Understanding the Immunobiology of Clinical Responses to CD19 CAR T Cell Adoptive Therapy In Lymphoma Patients
Project Leaders: Michael Jensen, M.D. and Stanley Riddell, M.D.
Core D. Biologics Manufacturing: Produces oligonucleotide, antibody and cellular therapy products
Core Leader: Christine Brown, Ph.D.
Career Enhancement Program: Funds junior investigator career development activities
Developmental Research Program: Funds early stage projects with potential to become full SPORE projects